About
A senior biotechnology executive with Venture Capital, Board of Directors, and Management…
Activity
-
We're thrilled to welcome Talia Fountain to the Compass Therapeutics team as our new Clinical Trial Associate! #CMPX #biotech #biotechnology…
We're thrilled to welcome Talia Fountain to the Compass Therapeutics team as our new Clinical Trial Associate! #CMPX #biotech #biotechnology…
Liked by Thomas Schuetz
-
I’m happy to share that I’m starting a new position as Head of Antibody Discovery US Large Molecule Research at Sanofi!
I’m happy to share that I’m starting a new position as Head of Antibody Discovery US Large Molecule Research at Sanofi!
Liked by Thomas Schuetz
-
At the 2024 ASCO Annual Meeting, we'll present data from the Phase 1 Study of our novel anti-CD137 antibody, CTX-471, and its safety and anti-tumor…
At the 2024 ASCO Annual Meeting, we'll present data from the Phase 1 Study of our novel anti-CD137 antibody, CTX-471, and its safety and anti-tumor…
Liked by Thomas Schuetz
Experience & Education
-
Compass Therapeutics Inc.
View Thomas’s full experience
See their title, tenure and more.
or
More activity by Thomas
-
Today, we reported our annual 2023 financial results and shared corporate and clinical updates. Read the full press release…
Today, we reported our annual 2023 financial results and shared corporate and clinical updates. Read the full press release…
Liked by Thomas Schuetz
-
Dana-Farber has launched a new oncology program designed for adults with intellectual and/or developmental disabilities. The Neuro-Inclusive Oncology…
Dana-Farber has launched a new oncology program designed for adults with intellectual and/or developmental disabilities. The Neuro-Inclusive Oncology…
Liked by Thomas Schuetz
-
The women of Compass celebrate each other daily, but especially today on International Women’s Day! We work together to advance research in cancer…
The women of Compass celebrate each other daily, but especially today on International Women’s Day! We work together to advance research in cancer…
Liked by Thomas Schuetz
-
We're proud to announce the publication of very promising pre-clinical data for our next generation PD-1/PD-L1 bispecific antibody, CTX-8371, in the…
We're proud to announce the publication of very promising pre-clinical data for our next generation PD-1/PD-L1 bispecific antibody, CTX-8371, in the…
Liked by Thomas Schuetz
-
Today is World Cholangiocarcinoma Awareness Day! Today our team wears #GreenforCCA. Learn more about the disease from the Cholangiocarcinoma…
Today is World Cholangiocarcinoma Awareness Day! Today our team wears #GreenforCCA. Learn more about the disease from the Cholangiocarcinoma…
Liked by Thomas Schuetz
-
February is Cholangiocarcinoma (CCA) Awareness Month. This month, join us in raising awareness about this devastating cancer of the bile duct. Learn…
February is Cholangiocarcinoma (CCA) Awareness Month. This month, join us in raising awareness about this devastating cancer of the bile duct. Learn…
Liked by Thomas Schuetz
-
We are pleased to announce that Natalie Warholic has joined our team as Director of Clinical Operations. Welcome, Natalie! Learn more about Compass…
We are pleased to announce that Natalie Warholic has joined our team as Director of Clinical Operations. Welcome, Natalie! Learn more about Compass…
Liked by Thomas Schuetz
-
Vered Bisker-Leib, PhD, MBA, Compass President and COO, will present at the Jefferies London Healthcare Conference on Thursday, November 16, at 2:30…
Vered Bisker-Leib, PhD, MBA, Compass President and COO, will present at the Jefferies London Healthcare Conference on Thursday, November 16, at 2:30…
Liked by Thomas Schuetz
-
OrbiMed is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private…
OrbiMed is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private…
Liked by Thomas Schuetz
-
I’m happy to share that I’m starting a new position as Managing Director, Co-Head of ECM at Cantor Fitzgerald!
I’m happy to share that I’m starting a new position as Managing Director, Co-Head of ECM at Cantor Fitzgerald!
Liked by Thomas Schuetz
-
Cancer research begins with dedicated scientists who work every day to find treatments for patients. Here at Compass, we are proud of moving cancer…
Cancer research begins with dedicated scientists who work every day to find treatments for patients. Here at Compass, we are proud of moving cancer…
Liked by Thomas Schuetz
-
Proud of this news today from our Foundation. https://lnkd.in/evqS5rAA
Proud of this news today from our Foundation. https://lnkd.in/evqS5rAA
Liked by Thomas Schuetz
People also viewed
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Thomas Schuetz in United States
-
Thomas Schuetz
-
Thomas Schuetz
--
-
Thomas Schuetz
--
-
Thomas Schuetz
Field Reporting Specialist at Reliable Reports
23 others named Thomas Schuetz in United States are on LinkedIn
See others named Thomas Schuetz